Telomere maintenance is essential for cancer growth. Induction of telomere dysfunction, for example, by inhibition of telomeric proteins or telomerase, has been shown to strongly enhance cancer cells' sensitivity to chemotherapies. However, it is not clear whether modulations of telomere maintenance constitute cancer cellular responses to chemotherapies. Furthermore, the manner in which anti-cancer drugs affect telomere function remains unknown. In this study, we show that anthracyclines, a class of anti-cancer drugs widely used in clinical cancer treatments, have an active role in triggering telomere dysfunction specifically in telomerase-positive cancer cells. Anthracyclines interrupt telomere maintenance by telomerase through the downregulation of PinX1, a protein factor responsible for targeting telomerase onto telomeres, thereby inhibiting telomerase association with telomeres. We further demonstrate that anthracyclines downregulate PinX1 by inducing this protein degradation through the ubiquitin-proteasome-dependent pathway. Our data not only reveal a novel action for anthracyclines as telomerase functional inhibitors but also provide a clue for the development of novel anti-cancer drugs based on telomerase/telomere targeting, which is actively investigated by many current studies.
Introduction
Telomerase reactivation has been identified as a key step in human cellular tumorigenesis, and it is also responsible for the hallmark immortalization phenotype of cancer cells; this is because of its effect on telomere maintenance. Consequently, targeting the pathway of telomere maintenance by telomerase represents a novel approach for anti-cancer therapy. Understanding how this carcinogenic pathway is regulated in cancer cells is highly desirable for this purpose.
Telomere is the terminal DNA component of the linear chromosome. Owing to the incapacity of the DNA polymerase to fully replicate the very end sequences of double-stranded chromosomes, telomeric DNA would shorten at a constant rate in each cell division (De Lange, 1998; Blackburn, 2000) . When telomere shortens to a critical point, it would trigger DNA-damage responses (DDRs) at the chromosomal ends and force normal cells into senescence. By contrast, telomerase, which is suppressed in normal somatic cells, is reactivated to counteract telomere shortening in nearly all human cancer cells, and these malignant cells enjoy telomere-length maintenance and unlimited proliferative capacity (Kim et al., 1994; Autexier and Greider, 1996; Collins, 2000) .
Telomerase is a ribonucleoprotein reverse transcriptase specialized for de novo synthesis of telomeric DNA at chromosomal ends after each cell cycle. The core of this enzyme from all species is minimally composed of a protein-catalytic subunit and a single-stranded RNA called TERT and TR, respectively (Nugent and Lundblad, 1998; Collins, 2006) . The expression of TERT has been demonstrated as a rate-limiting step in human cellular telomerase activation, and it is suppressed by multiple tumor-suppressor pathways in normal human cells but is activated by numerous oncogenic transcription factors (Meyerson et al., 1997; Liu et al., 2000; Cong et al., 2002; Lin and Elledge, 2003; Goueli and Janknecht, 2004) . After its expression, regulations of the subcellular transportation of the TERT protein contribute to telomere homeostasis maintenance in telomerase-positive cancer cells. It has been shown that the expressed TERT undergoes a highly programmed subcellular transportation before it reaches its final functional site at the telomere (Wong et al., 2002; Tomlinson et al., 2006) . Moreover, regulations of the TERT subcellular transportation may have implications in the two central issues of telomerase/ telomere biology, that is, telomerase biogenesis and telomerase telomere recruitment in vivo. Moreover, alterations of TERT subcellular distributions have been observed in cancer cellular responses to certain cytotoxic-damaging stimuli, such as DNA damages and oxidative stresses, emphasizing that modulations of TERT transportation, thereby regulating the pathway of telomere maintenance by telomerase, may have an important impact on cancer cell survival under anticancer treatments. However, how TERT transportations are regulated in vivo is still poorly understood. Undoubtedly, elucidating these questions will facilitate the development of novel anti-cancer therapies based on telomerase/telomere biology.
Telomere maintenance by telomerase requires telomerase interplay with telomeric DNA. In cells, telomeric DNA is coated with a set of specialized telomeric proteins. Six telomere-constitutive protein components have been identified, including Pot1, TPP1, TIN2, TRF1, TRF2 and Rap1 (de Lange, 2005) . These six telomeric proteins form a complex called shelterin at telomere ends, and they function as a whole to protect telomeric DNA from being recognized as DNA broken by the DNA damage-repair machinery but, meanwhile, they also prevent telomerase from having access to its functional substrate telomeric DNA (de Lange, 2005; Palm and de Lange, 2008) . Therefore, communication with the shelterin complex is an essential step for the telomerase to carry out its telomere maintenance action. Recent studies have revealed that in addition to participating in the shelterin formation, the Pot1-TPP1 heterodimers have crucial roles in recruiting telomerase function on telomeres (Xin et al., 2007) . The studies suggest that the Pot1-TPP1 dimer may function as the telomerase receptor at telomeres for guiding this enzyme's access to its functional default substrates. However, given that the Pot1-TPP1 dimer has been considered as a constitutive telomeric component, how the telomerase ribonucleoprotein complex, which is clearly assembled within nuclei outside the telomere ends, is targetedly delivered onto the Pot1-TPP1 unit still remains unknown.
The nucleolar protein PinX1 was originally found as an interacting protein of both the telomeric protein TRF1 and the telomerase catalytic protein subunit TERT (Zhou and Lu, 2001) . Although PinX1-TRF1 interaction has not been functionally characterized, the binding of PinX1 to TERT was experimentally shown to have a telomerase activity (TA)-inhibitory effect, suggesting that this protein might function as a cellular telomerase inhibitor. However, it is intriguing that the PinX1 expression appears not to be affected in most human cancer cells (Akiyama et al., 2004; Chang et al., 2004; Hawkins et al., 2004) . We recently found that depletion of the PinX1 expression has an effect in suppressing telomerase association with the Pot1-containing telomeric protein complex, and it significantly shortens telomere lengths in telomerase-positive cancer cells. Moreover, silencing PinX1 makes these affected cancer cells more sensitive to DNA damage-induced telomere dysfunction and to apoptosis in telomerasepositive cancer cells (Zhang et al., 2009 ). These novel findings not only suggest that there is a PinX1-mediated pathway for telomere maintenance in cancer cells but they also indicate that the functional maintenance of this pathway may have an important impact on cancer cells' survival under DNA-damaging stresses. Therefore, it is worthwhile to further investigate whether modulations of this pathway are involved in cancer cellular responses to anti-cancer drug treatments.
Anthracyclines rank among the most-effective anticancer drugs ever developed. It has generally been accepted that anthracyclines function as a topoisomerase poison and that they kill cancer cells through inducing DNA double-stranded break (DSB) damage (Minotti et al., 2004) . In this study, we show that the anthracyclines doxorubicin (DOX) and its analog epirubicin (EPI) also have an effect on inducing telomere dysfunction, specifically in telomerase-positive cancer cells. We further demonstrate that both DOX and EPI perform this novel effect by triggering PinX1 into a proteasome-dependent protein degradation pathway, thereby disrupting the telomere maintenance by telomerase in affected cancer cells. Therefore, we for the first time provide the direct evidence that modulations of PinX1-dependent telomere maintenance by telomerase constitute cancer cellular responses to certain anticancer drug treatments, such as anthracyclines, and that this may have important consequences for their anti-cancer effects. These novel findings may also provide a clue for designing new anti-cancer drugs based on targeting telomere maintenance by telomerase.
Results
Inducible telomere dysfunction is specifically associated with anthracycline treatments in telomerase-positive cancer cells The induction of DNA DSB damage is a common method for the action of most anti-cancer drugs to treat tumors. It has been shown that telomere maintenance has great impact on cancer cellular responses to DSBs. Therefore, it is interesting to ask whether modulations of telomere maintenance constitute cancer cellular responses to these anti-cancer drug treatments. One of the major functions of telomeres is to protect chromosomal ends from being recognized as DNA DSBs. Consequently, telomere dysfunction evokes the activation of DDRs at chromosomal ends, represented by foci accumulation of activated DNA damage-responding protein factors, such as ATM, 53BP1 and gH2AX, at telomeres. This particular event is defined as TIFs (telomere dysfunction-induced DNA-damaging foci). TIFs can be judged by co-localizations of DNAdamaged foci (such as the gH2AX foci) with telomere markers (such as telomeric DNA or telomeric protein components) (Takai et al., 2003; Denchi and de Lange, 2007) . We examined TIFs in the two telomerase-positive cancer cell lines of HepG2 and MCF7 during the courses of their responses to different DSB-inducing anti-cancer drugs, including etoposide (Et) and the anthracyclines DOX and its analog EPI. As shown in Figure 1a , all these drugs induced robust DDRs both in MCF7 and HepG2 cancer cells, as indicated by foci formations of gH2AX. Notably, we found that there were substantial fractions of the gH2AX foci co-localized with the detecting signals for the telomeric constitutive protein component TRF1 in both DOX-and EPI-treated cells ( Figure 1a) ; this suggests that telomere dysfunction is present in the courses of cancer cellular responses to these two drug treatments. Moreover, both DOX and EPI could induce telomere dysfunction in a dosedependent manner, with this being more obvious for EPI treatment (Figure 1b) . However, incidences of telomere dysfunction were only occasionally observed in Et-treated cells ( Figure 1a ). In fact, we found that TIF incidences were also not present in tested cancer cells, which had been treated with another kind of DSBinducing anti-cancer drug camptothecin (data not shown). The effect of anthracyclines on inducing telomere dysfunction was also examined in telomerasenegative BJ normal human fibroblasts. Interestingly, we found that, in the ranges of the indicated dosages, neither DOX nor EPI caused obvious TIFs in these normal human cells ( Figure 1c ). In fact, we also found that both DOX and EPI have no effects on increasing TIF incidences in telomerase-negative U2OS human cancer cells (data not shown). Thus, these results suggest that anthracyclines have an effect on inducing telomere dysfunction in cancer cells through a telomerasedependent pathway.
Anthracycline treatments suppress telomerase association with telomeres without affecting telomerase expression in cancer cells
The findings that the anthracyclines DOX and EPI cause telomere dysfunction specifically in telomerasepositive cancer cells indicated that this class of anticancer drug might affect a mechanism involved in the telomere maintenance by telomerase. Therefore, we first analyzed the telomerase enzymatic activities and their expression levels in cancer cells before and after treatments of these reagents. As indicated in Figures  2a and b, we found that neither DOX nor EPI caused significant alterations in total telomerase enzymatic activity (assayed by the standard TRAP) or in the TERT expression (by reverse transcriptase-PCR) in the tested MCF7 and HepG2 cancer cell lines. We next detected whether DOX and EPI affected the telomerase association with telomeres, a prerequisite step for the action of telomerase on telomere maintenance. The telomere associated with telomerase was monitored by detecting the amounts of the telomerase protein TERT in Pot1-containing telomeric protein complex. Flag-TERT-stable HepG2 cells were first used for testing this hypothesis. As shown in Figure 2c , the expression levels of Flag-TERT in stable cells did not change either before or after drug treatments. However, the amounts of Flag-TERT in the Pot1 immunoprecipitates were significantly reduced upon EPI and DOX treatments ( Figure 2d ). As the control, we showed that the amounts of the Flag-TERT protein in the Pot1 immunoprecipitates were not affected by Et treatment in the same cells ( Figure 2d ). Like cases observed in Flag-TERT-stable HepG2 cells, anthracycline treatments also did not affect the expressions of the endogenous TERT protein but significantly reduced its association with Pot1 in non-transfected HepG2 cells upon the treatments (Figures 2e and f) . Therefore, the anthracyclinesinduced telomere dysfunction is associated with the reduction of telomerase association with telomeres in cancer cells.
Anthracyclines block telomerase association with telomeres by downregulating PinX1 expression
We recently demonstrated that the nucleolar protein PinX1 has an effect of mediating telomerase association with the Pot1-containing telomeric protein complex in cancer cells, and that the disruption of this pathway by PinX1 silencing renders telomeres prone to dysfunction in telomerase-positive cancer cells under DNA-damaging stress conditions (Zhang et al., 2009) . We thus tested whether anthracyclines-induced telomere dysfunction is related to suppressing this PinX1-dependent telomere maintenance by telomerase. Western blotting assays indicated that an obvious inducible downregulation of the PinX1 protein expression could be detected in Flag-TERT-stable HepG2 cells as early as 6 h after DOX and EPI treatments and that it could be sustained for up to 24 h of observation (Figure 3a) . However, the expression levels of the PinX1 protein remained unchanged in the same cells before and after Et treatment (Figure 3a) . To make sure that this inducible PinX1 downregulation is responsible for the effect of anthracyclines on blocking telomerase association with telomeres and for inducing telomere dysfunction in cancer cells, full-length PinX1 was introduced into Flag-TERTexpressing HepG2 cells through a recombinant lentiviral infection, and the overexpression of PinX1 in Flag-TERT-stable cells was confirmed by western blotting assay (Figure 3c) . Interestingly, the expression levels of exogenous PinX1 could also be partially downregulated by EPI treatment (Figure 3c ). However, the remaining PinX1 protein expression levels seemed to be sufficient to suppress the inducible telomere dysfunction in these infected cells by means of EPI treatment. Incidences of the EPI-induced telomere dysfunction were significantly decreased in PinX1-overexpressing cells than in uninfected control cells (Figure 3e ). In addition, as had been predicted, PinX1 overexpression significantly attenuated the effect of EPI on inhibiting the telomerase/telomere association ( Figure 3d ). We also conducted analysis to discover whether silencing the endogenous PinX1 expression could enhance EPI-induced telomere dysfunction. A PinX1 short-hairpin RNA (shRNA) was introduced into Flag-TERT-stable HepG2 cells through a recombinant lentiviral infection, and significant suppression of endogenous PinX1 expression by shRNA was confirmed by immunoblotting assay (Figure 3c) . Acutely silencing the endogenous PinX1 expression did not cause obvious telomere dysfunction in affected cells under their normal cultural conditions (Figure 3e ), but incidences of the inducible telomere dysfunction by EPI were increased remarkably in shRNA-infected cells than Anthracyclines disrupt telomere maintenance by telomerase B Zhang et al in control cells ( Figure 3e ). Next, we examined the effects of DOX and EPI on PinX1 expression in telomerase-negative BJ normal fibroblasts and in U2OS cancer cells, and we found that both can be induced to exhibit a dose-dependent downregulation of PinX1 expression upon DOX and EPI treatments (Figure 3b ), thereby indicating that induction of a PinX1 decrease is a general effect of anthracyclines in human cells. However, unlike the case observed for telomerase-positive cancer cells, PinX1 overexpression or silencing PinX1 expressions in telomerase-negative BJ cells (Figure 3f , left panel) and in U2OS cells (data not shown) has no effect in inducing telomere dysfunction with and without the anthracyclines (Figure 3f , right panel). Thus, these results may suggest that the effect of anthracyclines on inducing PinX1 downregulation to trigger telomere dysfunction is dependent on whether the affected cell is addicted to telomerase for its telomere maintenance. Therefore, we propose that anthracyclines induce a PinX1 decrease to evoke telomere dysfunction in telomerase-positive cancer cells, but not in telomerase-negative human cells, through disturbing a PinX1-dependent pathway for recruiting telomerase to maintain telomeres.
Anthracyclines downregulate PinX1 expression by inducing this protein degradation through the ubiquitin-proteasome pathway The finding that anthracycline stimulation can also downregulate ectopic-expressed PinX1 protein levels prompted us to consider whether these reagents might affect this protein stability. Supporting this suggestion, reverse transcriptase-PCR assays indicated that the expression levels of the PinX1 mRNA transcripts did not show detectable changes in HepG2 cells before and after EPI and DOX treatments (Figure 4a ). However, when these cells were pretreated with MG132, a reagent that can prevent protein degradation through the proteasome pathway, the effect of EPI and DOX on inducing PinX1 downregulation was significantly blocked (Figure 4b ). Interestingly, MG132 treatment had only a minor effect on PinX1 protein accumulation in HepG2 cells without EPI and DOX stimulation ( Figure 4b) ; this indicates that cellular expressed PinX1 Figure 4 Anthracyclines downregulate PinX1 expression by inducing this protein degradation through the ubiquitin-proteasomedependent pathway. (a) HepG2 cells were treated with DOX and EPI for the indicated periods. PinX1 mRNA expression levels were detected by RT-PCR assays. GAPDH as control for total RNA was used in the RT-PCR assays. (b) HepG2 cells were pretreated with ( þ ) or without (À) the proteasome inhibitor MG132 (10 mM) for 8 h before they were exposed to the indicated dosages of EPI and DOX, respectively. After 16 h of EPI and DOX treatments, nuclear extracts were prepared and subjected to IB assays with PinX1-specific antibodies. Lower panels showed the ratios of PinX1 to tubulin from densitometric analysis. The results were representative of the three experiments. (c) HepG2 cells were transfected with a plasmid encoding Flag-PinX1 or a vector control, and transfected cells were pretreated with MG132 (10 mM) for 4 h before they were exposed to DOX (1 mg/ml) and EPI (1 mg/ml), respectively. Twelve hours after anthracyclines treatments, ectopic-expressed Flag-PinX1 was immunoprecipitated from nuclear extracts by the anti-Flag M2 beads. The immunoprecipitates were subjected to IB assay with an anti-ubiquitin antibody. IB with the anti-Flag antibody shows equal amounts of the precipitated PinX1 proteins for each detecting samples.
Anthracyclines disrupt telomere maintenance by telomerase B Zhang et al proteins were not constantly undergoing proteasomemediated degradation but could be induced into this pathway upon both EPI and DOX treatments. As ubiquitination has been established as the major signal for directing proteins into the proteasome-mediated degradation pathway, we further detected whether both drugs have the effect of inducing PinX1 ubiquitination. As shown in Figure 4c , robust ubiquitination signals could be detectable in the PinX1 protein immunoprecipitates from MG132-pretreated HepG2 cells in the presence of EPI and DOX, but only faint ubiquitination signals were observed in the PinX1-immunoprecipitated products from MG132-pretreated HepG2 cells without EPI and DOX treatments. Thus, we propose that both EPI and DOX trigger a response of PinX1 ubiquitination, which in turn targets PinX1 degradation through the proteasome pathway.
Suppression of PinX1-dependent telomere maintenance by telomerase contributes to the cancer-killing effects of anthracyclines So far, we have revealed a novel effect for anthracyclines in inducing telomere dysfunction by suppression of PinX1-dependent telomere maintenance by telomerase. We proceeded to analyze whether blocking this pathway contributes to the cytotoxic effects of anthracyclines on cancer cells. We used annexin staining and flow cytometry as a sensitive, quantitative assay to detect cells both in early and late apoptosis. As shown in Figure 5a , EPI-induced cell apoptotic death incidences in HepG2 cells were significantly increased by PinX1 silencing, but were decreased remarkably by PinX1 overexpression. Accordingly, EPI-induced PARP (poly (ADP-ribose) polymerase) cleavage, a molecular marker for cell apoptosis, was significantly enhanced in the PinX1 knockdown HepG2 cells but was robustly blocked in PinX1-overexpressing cells (Figure 5b ). Therefore, we conclude that induction of PinX1 degradation, thereby suppressing telomere maintenance by telomerase, constitutes an anti-cancer action of anthracyclines.
Discussion
Telomere maintenance by telomerase has been identified as an essential pathway towards human cancer formation. Numerous studies have demonstrated that the interruption of this pathway, either by telomerase inhibition or by targeting the telomere structure per se, not only significantly inhibits cancer growth but also greatly enhances cancer sensitivity to the cytotoxic effects of most currently used anti-cancer chemotherapeutics (Nakamura et al., 2005; Shay and Wright, 2006; Harley, 2008; Uziel et al., 2010) . Therefore, it can be expected that the development of these telomere/ telomerase-targeting drugs will greatly improve the outcome of current anti-cancer therapies. Many efforts have been made to develop specific telomerase enzymatic inhibitors. Two decades have passed since this enzyme was characterized, but as yet a specific inhibitor has not been discovered. On the other hand, researches have revealed that the process of telomere maintenance by telomerase in cancer cells involves multiple regulatory steps, such as biogenesis of the telomerase ribonucleoprotein complex and recruitment of telomerase onto telomeres, suggesting that interferences of these events, without the need of wiping out TA per se, can also display the same outcome as do the telomerase inhibitors (Collins, 2006; Bianchi and Shore, 2008; Gallardo et al., 2008) . Most recently, we have demonstrated that the nucleolar protein PinX1 has a role in mediating telomerase association with telomeres in cancer cells, and that disruption of this PinX1-dependent telomerase/telomere recruitment pathway, for example, by PinX1 silencing, significantly shortens telomere lengths, inhibits tumorigenesis and also enhances their sensitivity to the cytotoxic effects of DNAdamaging reagents in telomerase-positive cancer cells. These results thus indicate that maintenance of this PinX1-dependent telomerase/telomere recruiting pathway is critical for telomere stability in cancer cells under both their normal and damaging growth conditions, consequently with medical implications in anti-cancer therapy. In this study, we provide evidence that inducible downregulation of PinX1, thereby causing acute telomere dysfunction, contributes to the cancerkilling effects of the chemotherapeutic anthracyclines. These findings further suggest that this PinX1-dependent telomere maintenance by a telomerase pathway can provide novel druggable targets for the currently pursued telomere/telomerase-based anticancer therapies. Anthracyclines represent a class of chemotherapeutics that have long been widely used in clinical cancer treatments. DOX is one of the first generation of anthracyclines. By different chemical modifications, DOX can be derived to more than hundreds of analogs, including the EPI used in this study. This property makes anthracyclines a potential with a still-improvable therapeutic index. Therefore, they may be regarded as the first evergreen anti-cancer drugs to be developed. The induction of DNA DSBs through the inhibition of topoisomerases has been identified as a major function of anthracyclines in killing cancers. Interestingly, we showed in this study that anthracyclines also have an active role in inducing telomere dysfunction in telomerase-positive cancer cells, and that this may constitute one of the anti-cancer effects of these drugs. This activity seems to be unrelated to their known DNAdamaging effect because it is not present in other topoisomerase poisons, such as camptothecin and Et. Instead, we propose that this effect is caused by a property of anthracyclines which downregulates the PinX1 protein expression, which in turn disrupts the interplay between telomerase and telomeres, therefore affecting telomere stability under DNA-damaging stress. Again, such an activity of downregulating the PinX1 expression is not found in other kinds of DNA damage inducers. Therefore, we identify a novel effect for anthracyclines as an inhibitor of telomere maintenance by telomerase through suppressing the PinX1 expression.
It is notable that the nature of anthracyclines binding to the G-quanduplex of telomeres may also contribute to the effect of these drugs in inducing telomere dysfunction (Mergny and Helene, 1998) . We consider that anthracyclines may cause telomere dysfunction through two independent mechanisms: (1) by binding to the G-quanduplex, and increasing its melting temperature, these drugs may hamper telomerase access to its functional sites at telomeres; and (2) while, by disrupting telomerase/telomere recruitment through downregulating the PinX1 expression, anthracyclines inhibit telomerase association with telomeres, thereby displaying a How anthracyclines regulate PinX1 expression still remains to be elucidated. Our data suggest that anthracyclines might affect PinX1 protein stability by inducing this protein into the ubiquitin-proteasomemediated degradation pathway. The fact that PinX1 can be regulated at the level of protein stability has also been reported recently. Wang et al. (2010) showed that pololike kinase 1 can bind and phosphorylate PinX1, thereby signaling PinX1 degradation through the ubiquitinproteasome pathway. However, because we found that suppression of polo-like kinase 1 by small-interfering RNA did not affect anthracycline-induced PinX1 downregulation (data not shown), we exclude that anthracycline stimulates PinX1 degradation through the reported polo-like kinase 1 pathway. It was reported that anthracyclines can activate some kinds of protein kinases, which may phosphorylate different proteins and resulting in their degradation (Laurent and Jaffrezou, 2001; Small et al., 2003) . As PinX1 contains many potential phosphorylation sites, we speculate that the degradation of PinX1 stimulated by anthracyclines might be through kinase pathways other than the polo-like kinase 1 pathway. Clearly, further works are required to clarify the mechanisms of degradation of PinX1 by anthracyclines in detail.
Although we suggest that the inducible downregulation of PinX1, thereby interrupting telomerase binding to telomeres, contributes to the effect of anthracyclines on inducing telomere dysfunction in telomerase-dependent cancer cells, it should be noted that this inducible downregulation of PinX1 per se appears not to be the cause of acute telomere dysfunction induced by anthracyclines; this is because acute depletion of PinX1 by PinX1 shRNA virus infection does not cause obvious telomere dysfunction in affected cancer cells under their normal cultural conditions (Figure 3e ). This is unlike our previous observations (Zhang et al., 2009 ) that chronic suppression of PinX1 eventually results in telomere dysfunction in PinX1 shRNA-stable cells, presumably by telomere shortening. However, in both cases, PinX1 depletion renders telomere prone to instability in the presence of chromosomal DNA damages. One possibility is that internal DNA damages in chromosomes might elicit a signal to affect telomere stability and that this could be antagonized by the presence there of telomerase. Alternatively, telomereassociated telomerase might have the effect of suppressing the activation of DDRs at chromosomal ends under cancer cellular DNA-damaging stresses. No matter what the case is, it is certain that telomerase maintains telomeres in cancer cells by more than its known action on counteracting telomeric DNA shortening. Characterizing these still-unknown functions for this enzyme at telomeres will permit new insights into how telomerase facilitates cancer development and how these functions might be used as targets for anti-cancer therapy.
In summary, the results here, together with our previous findings, suggest that the PinX1-mediated telomerase/telomere-delivering pathway can provide novel druggable targets for development of telomerase/ telomere-based anti-cancer drugs. The finding that this functional pathway can be specifically disrupted by DOX and EPI not only elucidates a new mechanism for the anti-tumor activity of anthracyclines but also provides a new clue for development of the new generation of anti-cancer drugs, based on targeting the pathway of telomere maintenance by telomerase. As anthracyclines can derivate into thousands of analogs by different chemical modifications, it is interesting to find whether these modifications could produce a de novo anthracycline that acts as a potent telomerase functional inhibitor.
Materials and methods
Cell lines and reagents MCF7, HepG2, BJ and U2OS cells were maintained in a Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin at 37 1C in 5% CO 2 . Cells were treated with Et (Sigma, St Louis, MO, USA), DOX (Sigma) or EPI (Sigma) at the indicated concentrations.
Antibody sources are as follows: Rabbit polyclonal antibodies against PinX1 were purchased from Proteintech Group Inc. (Chicago, IL, USA). Rabbit polyclonal antibodies against Pot1 and rabbit mAB against TERT were purchased from Abcam (Cambridge, UK). Rabbit mAB against ubiquitin, mouse mAB against PARP, rabbit mAB against phospho-histone H2AX AB were purchased from Cell Signaling Technology (Beverly, MA, USA). Mouse mAB against FLAG were purchased from Sigma. Rabbit polyclonal antibodies against tubulin were purchased from Santa Cruz Biotechnology (California, CA, USA). Mouse mAB against TRF1 were purchased from GeneTex (San Antonio, TX, USA).
Construction of PinX1 cDNA and small-hairpin RNA lentiviral vector A plasmid-containing PinX1 cDNA was cloned into a pCDH cDNA expression lentivector (System Biosciences, Mountain View, CA, USA), and then co-transfected into 293 cells with a packaging plasmids mix to generate a recombinant lentivirus in accordance with the manufacturer's instructions. The construction of PinX1-shRNA lentivirus vector was reported previously (Zhang et al., 2009) .
Reverse transcription-PCR
The expression of PinX1 and hTERT mRNA was analyzed by reverse transcriptase-PCR assay. The total RNA (2 mg), which was extracted using TRIZOL (Invitrogen, Carlsbad, CA, USA), was used for cDNA synthesis with MMLV (Moloney murine leukemia virus) reverse transcriptase (Promega, Madison, WI, USA). cDNA was subjected to PCR with primers for PinX1 (forward, 5 0 -ATGTCTATGCTG GCTGAACGTCGG-3 0 and reverse, 5 0 -GCTCTTCTTCTTG GCCACTCG-3 0 ), hTERT (forward, 5 0 -GTATGGCTGCGT GGTGAA-3 0 and reverse, 5 0 -TCAGTCCAGGATGGTCTT GAA-3 0 ) and GAPDH (forward, 5 0 -GTTCGACAGTCAG CCGCATCT-3 0 and reverse, 5 0 -CCTGCAAATGAGCCC CAGCCT-3 0 ). Amplification consisted of 30 cycles of 30 s at 94 1C, 30 s at 55 1C and 60 s at 72 1C.
Immunoprecipitation and immunoblotting
Cells (2 Â 10 7 ) were lysated and sonicated in a cell lysis buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 10 mg/ml protease inhibitor cocktail) on ice. Protein concentrations were determined using the BCA kit (Pierce, Rockford, IL, USA). Equal amounts of cell lysates precleared with proteinA/G agarose (Calbiochem, Darmstadt, Germany) were incubated with the primary antibody with gentle rocking overnight at 4 1C. Immune complexes were then precipitated by incubating them with proteinA/G agarose for 2 h at 4 1C.
Immunoprecipitates were washed five times with a cell lysis buffer. After boiling in 20 ml 2 Â SDS sample buffer, the samples were analyzed by western blotting. Western blot analysis followed the standard procedures and was repeated at least thrice for each protein tested.
In vivo ubiquitination assay Cells were lysed in SDS containing a buffer (50 mM Tris, pH 7.5, 0.5 mM EDTA, 1% SDS and 1 mM dithiothreitol), and boiled for 10 min to denature the proteins. Lysates were clarified by centrifugation at 14 000 r.p.m. on a microcentrifuge for 10 min. Equal amounts of protein were diluted 10 times with an immunoprecipitation buffer (50 mM Tris, pH 7.5, 2 mM EDTA, 150 mM NaCl and 0.5% NP-40 and protease inhibitor cocktail). The diluted lysates were applied to immunoprecipitation with Flag M2 beads (Sigma) and immunoblotting with an anti-ubiquitin antibody.
Immunofluorescence Cells grown on coverslips were fixed in 4% paraformaldehyde. Fixed cells were permeabilized with 1% Triton-X100 and blocked with 10% normal goat serum. Cells were then incubated with primary antibody for 2 h at 37 1C in a humid chamber, washed in phosphate-buffered saline and were then incubated with the secondary antibodies for 1 h. The secondary antibodies, including DyLight 549-conjugated Goat anti-Mouse IgG (Thermo Scientific, Rockford, IL, USA) and Alexa Fluor 488-conjugated goat anti-rabbit IgG (Invitrogen), were used at dilutions of 1:300. Nuclei were stained with DAPI (4 0 ,6 0 -diamidino-2-phenylinodole, Sigma). Immunofluorescence images were captured using the Olympus FluoView confocal microscopes and analyzed with FV10-ASW viewer software (Olympus, Tokyo, Japan). TIFs were evidenced by co-localizations of the DNA-damage factor gH2AX with the constitutive telomere protein component TRF1. A total of 400 cells were counted for each observation, and cells with >5 spots of gH2AX and TRF1 co-localization signals were considered as TIF positive (Takai et al., 2003; Denchi and de Lange, 2007) .
TA assay
Telomerase activity was measured using a TRAPeze telomerase detection kit (Chemicon, Temecula, CA, USA) in accordance with the manufacturer's instructions. The samples were electrophoresed on a 12.5% non-denaturing PAGE in 0.5 Â Tris-borate-EDTA buffer and visualized by SYBG green (Invitrogen). Quantification was performed using the Quantity-One software for Bio-Rad Image analysis systems (Bio-Rad Laboratories, Hercules, CA, USA). The amount of the telomerase product was calculated by using the following formula: TPG (U) ¼ (XÀB)/C:(rÀB)/Cr Â 100, where TPG is the total product generated, X sample signal, B background signal intensity, C the 36-bp internal PCR control and r the TSR8 quantification control. Relative TA was calculated by dividing TA at certain point to baseline TA.
Annexin V-propidium iodide staining and flow-cytometry analysis To determine the amount of apoptosis cells, Alexa Fluor 488 annexin V/propidium iodide apoptosis assay kit (Invitrogen) was used. Cells treated by the indicated doses of drugs were harvested, rinsed with cold phosphate-buffered saline and incubated with Alexa Fluor 488 annexin V/propidium iodide according to the manufacturer's instructions. Cells were analyzed by flow cytometry (Becton Dickinson, San Jose, CA, USA).
